Potential targets on Sanofi’s radar
09/09/20 -"In line with its strategy of expanding its focus on the immuno-oncology space and strengthening its internal R&D pipeline, Sanofi has spent €5.2bn on the acquisition of two small biotech firms ..."
Pages
70
Language
English
Published on
09/09/20
You may also be interested by these reports :
26/10/20
The acquisition of Asklepios BioPharmaceutical (AskBio), while not a bargain, is a great move into the really hot topic of gene therapy. Based on the ...
23/10/20
While Somatuline lost pace in Q3 – due to lower patient diagnoses amidst the pandemic – Cabometyx witnessed an acceleration on the back of a solid ...
22/10/20
The building block of any European equity portfolio, Pharmas, has lost its bearings. Markets, which are ready to pay for anything that smacks of ...
16/10/20
After a disappointing Q2 (-4% CER sales growth), Roche had some respite in Q3 (+1%) – though below expectations, largely driven by diagnostics due to ...